144 related articles for article (PubMed ID: 38014753)
1. Propensity score-incorporated adaptive design approaches when incorporating real-world data.
Lu N; Chen WC; Li H; Song C; Tiwari R; Wang C; Xu Y; Yue LQ
Pharm Stat; 2024; 23(2):204-218. PubMed ID: 38014753
[TBL] [Abstract][Full Text] [Related]
2. Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data.
Chen WC; Wang C; Li H; Lu N; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2020 May; 30(3):508-520. PubMed ID: 32370640
[TBL] [Abstract][Full Text] [Related]
3. Propensity score-integrated approach to survival analysis: leveraging external evidence in single-arm studies.
Chen WC; Lu N; Wang C; Li H; Song C; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2022 May; 32(3):400-413. PubMed ID: 35675348
[TBL] [Abstract][Full Text] [Related]
4. Leverage multiple real-world data sources in single-arm medical device clinical studies.
Lu N; Wang C; Chen WC; Li H; Song C; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2022 Jan; 32(1):107-123. PubMed ID: 33844621
[TBL] [Abstract][Full Text] [Related]
5. Propensity score-integrated composite likelihood approach for incorporating real-world evidence in single-arm clinical studies.
Wang C; Lu N; Chen WC; Li H; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2020 May; 30(3):495-507. PubMed ID: 31707908
[TBL] [Abstract][Full Text] [Related]
6. Propensity score-integrated power prior approach for augmenting the control arm of a randomized controlled trial by incorporating multiple external data sources.
Lu N; Wang C; Chen WC; Li H; Song C; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2022 Jan; 32(1):158-169. PubMed ID: 34756158
[TBL] [Abstract][Full Text] [Related]
7. Practical considerations of utilizing propensity score methods in clinical development using real-world and historical data.
Li Q; Lin J; Chi A; Davies S
Contemp Clin Trials; 2020 Oct; 97():106123. PubMed ID: 32853779
[TBL] [Abstract][Full Text] [Related]
8. Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical data.
Liu M; Bunn V; Hupf B; Lin J; Lin J
Stat Med; 2021 Sep; 40(22):4794-4808. PubMed ID: 34126656
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of diagnostic tests for low prevalence diseases: a statistical approach for leveraging real-world data to accelerate the study.
Chen WC; Li H; Wang C; Lu N; Song C; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2021 May; 31(3):375-390. PubMed ID: 33615997
[TBL] [Abstract][Full Text] [Related]
10. Bayesian Divide-and-Conquer Propensity Score Based Approaches for Leveraging Real World Data in Single Arm Clinical Trials.
Baron E; Zhu J; Tang RS; Chen MH
J Biopharm Stat; 2022 Jan; 32(1):75-89. PubMed ID: 35094643
[TBL] [Abstract][Full Text] [Related]
11. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
Sawamoto R; Oba K; Matsuyama Y
Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
[TBL] [Abstract][Full Text] [Related]
12. Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies.
Wang C; Li H; Chen WC; Lu N; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2019; 29(5):731-748. PubMed ID: 31530111
[TBL] [Abstract][Full Text] [Related]
13. Incorporating propensity scores for evidence synthesis under bayesian framework: review and recommendations for clinical studies.
Lin J; Lin J
J Biopharm Stat; 2022 Jan; 32(1):53-74. PubMed ID: 33998364
[TBL] [Abstract][Full Text] [Related]
14. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J
Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264
[TBL] [Abstract][Full Text] [Related]
15. The use of real-world data for clinical investigation of effectiveness in drug development.
Wang P; Chow SC
J Biopharm Stat; 2024 Mar; ():1-24. PubMed ID: 38519266
[TBL] [Abstract][Full Text] [Related]
16. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
Hiramatsu K; Barrett A; Miyata Y;
Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
[TBL] [Abstract][Full Text] [Related]
17. Dynamic incorporation of real world evidence within the framework of adaptive design.
Lin J; Liao R; Gamalo-Siebers M
J Biopharm Stat; 2022 Nov; 32(6):986-998. PubMed ID: 35730907
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
Yuan L; Rahman M; Concato J
Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
[TBL] [Abstract][Full Text] [Related]
19. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.
Dagenais S; Russo L; Madsen A; Webster J; Becnel L
Clin Pharmacol Ther; 2022 Jan; 111(1):77-89. PubMed ID: 34839524
[TBL] [Abstract][Full Text] [Related]
20. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
